A notable development is the termination of IGM’s collaboration with Sanofi (NYSE:NASDAQ:SNY), which has raised concerns about the company’s partnerships and future prospects. In response to ...

The end of IGM’s collaboration with Sanofi represents a significant setback. Such partnerships often provide smaller biotech firms with financial support, research and development resources, and ...

Sanofi has agreed another deal to flesh out its R&D pipeline, paying IGM Biosciences $150 million upfront to gain access to its engineered IgM antibody technology across six targets in oncology ...

Story May 8 - IGM Biosciences: Sanofi's termination of its 2022 collab with IGM Biosciences was the final nail in the coffin for the biotech’s research, given that it represented the last ...

France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US, saying it intends to spend "at least $20 billion" there by the ...

Wall Street strategists say they are cautious about US stocks right now despite US trade deals with the UK and China.

The company is also working with Sanofi to fund a Phase 4 study in adults 50–64 without high-risk conditions, as requested by the FDA. Financially, Novavax reaffirmed its 2025 forecast for R&D ...

With CAD 249.1 billion in core AUM at the end of October 2024, IGM Financial is the largest non-bank-affiliated domestic asset manager in the Canadian market. The largest Canadian banks and ...

The French drugmaker, one of the world's largest vaccine makers and a leader in anti-inflammatory drugs, said on Wednesday it plans to expand its US manufacturing capacity through direct investments ...

It also directed HRSA to reconsider a rebate plan from Sanofi that regulators had denied. As such, the decision is a mixed bag for hospital and pharmaceutical companies, which are frequently at ...